Allogeneic approaches are deemed the future of cell therapy due to their potential to reduce costs, increase accessibility and enhance availability. However as clinical readouts emerge, challenges associated with limited durability, solid tumour targeting and therapy immunogenicity are hindering their efficacies.
The Allogeneic Cell Therapies Summit Europe is returning in January to capture the clinical advances of European drug developers whilst addressing the specific challenges they face in development. These include European regulatory affairs, donor selection, scalable manufacturing and therapy persistence.
With continued investment and growth in the allogeneic space, join European leaders from Gadeta, Antion Biosciences, TC BioPharm, and many more, as well as the US leaders undertaking European trials. This includes Atara Bio and Adicet Bio, as they progress development of multiple cell types to produce the next-generation of safe, effective and accessible cell therapies in Europe.
Speakers: Blake Aftab, CSO, Adicet Bio Inc., Christopher Bravery, Consulting Regulatory Scientist, Independent Consultant, Cokey Nguyen, Chief Scientific Offier, Atara Biotherapeutics Inc., Dimitrios Wagner, Physician Scientist, BeCAT, Charite Universitatsmedizin Berlin, Emilio Cosimo, Director and Product Development Manager, TCBiopharm, Eric Halioua, President and Chief Executive Officer, PDC*line Pharma, Evren Alici, Head of Cell and Gene Therapy Group, Karolinska Institutet, Jan Spanholtz, Chief Scientific Officer - Research and Development Manager, Glycostem Therapeutics, John Maher, Chief Scientific Officer, Leucid Bio, Lior Raviv, CTO, Pluristem Therapeutics, Inc, Manal Morsy, Executive Vice President, Head of Global Regulatory Affairs, Athersys, Mark Throsby, Chief Scientific Officer, Gadeta, Marta Barisa< Senior Fellow, University College London, Michael Leek, Chief Of Executive and Founder, TCBiopharm, Michal Izrael, Vice President - Research, Development, Amyotrophic Lateral Sclerosis and Neurodegenerative Diseases, Kadimastem Ltd., Olivier Negre, Chief Scientific Officer, Smartimmune, Sven Kili, Chief Executive Officer, Antion Biosciences SA, Volker Huppert, Chief Development Officer, Glycostem Therapeutics
09:55 - 16:55